NEW HAVEN, Conn., June 18, 2019 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage
biopharmaceutical company with a portfolio of innovative,
late‑stage product candidates targeting migraine and neurological
diseases, including rare disorders, today announced the pricing of
its underwritten public offering of 6,976,745 of its common shares
at a price to the public of $43.00 per share. In
addition, Biohaven has granted the underwriters a 30-day option to
purchase up to an additional 1,046,511 common shares at the public
offering price, less underwriting discounts and commissions.
The gross proceeds from the offering are expected to be
approximately $300 million before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Biohaven. The offering is expected to close on
June 21, 2019, subject to customary
closing conditions.
Goldman Sachs & Co. LLC and Piper
Jaffray & Co. are acting as joint book-running managers
of the offering. Cantor Fitzgerald & Co., William Blair & Company, L.L.C., Canaccord
Genuity LLC and Oppenheimer & Co. Inc. are acting as
co-managers.
The offering is being made only by means of a prospectus.
When available, copies of the final prospectus related to the
offering may be obtained from the offices of Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, NY 10282, telephone: 1-866-471-2526,
facsimile: 212-902-9316 or by
emailing Prospectus-ny@ny.email.gs.com; or from Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis,
MN 55402, or by telephone at (800) 747-3924, or by email
at prospectus@pjc.com.
The shares will be issued pursuant to an effective shelf
registration statement on Form S-3 filed with the Securities and
Exchange Commission ("SEC") on June 17,
2019. Copies of the registration statement can be accessed
through the SEC's website at www.sec.gov. This press release
shall not constitute an offer to sell, or the solicitation of an
offer to buy, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-announces-pricing-of-300-million-public-offering-of-common-shares-300870971.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.